[ad_1]
During the last trading session, Illumina (ILMN) closed at $ 300.91, marking an increase of 1.14% over the previous day. This evolution exceeded the daily loss of 0.07% of the S & P 500. At the same time, the Dow Jones added 0.14% and the Nasdaq, a techie company, lost 0.22%.
Today, the company's stock of genetic testing tools grew by 4.48% last month. At the same time, the medical sector gained 0.45%, while the S & P 500 gained 4.58%.
ILMN will seek to show vigor as we approach the release of its next results. The company is expected to generate $ 1.40 EPS, down 8.14% from the same quarter last year. At the same time, Zacks' estimated consensus revenue forecasts net sales of $ 871.64 million, up 2.19% over the same period last year.
According to our consensus estimates for Zacks, analysts expect a profit of $ 6.05 per share and revenues of $ 3.53 billion. These totals would show variations of + 5.7% and + 5.97% compared to last year.
Investors should also note recent changes to analysts' estimates for ILMN. Recent revisions tend to reflect the latest short-term business trends. In this spirit, we can consider revisions of positive estimates as a sign of optimism about the company's business prospects.
Our research shows that these estimation changes are directly related to short-term share prices. Investors can benefit by using Zacks' ranking. This model takes into account these estimation changes and provides a simple and usable scoring system.
Ranging from # 1 (strong buy) to # 5 (solid sale), Zacks' ranking system has proven itself outside the outperformance audit, with # 1 stock returning on average + 25% per year since 1988. In recent years months, the estimate of Zacks Consensus EPS has increased by 0.05%. ILMN is currently ranked 3 by Zacks (pending).
By searching through the assessment, ILMN currently has a P / E ratio of 49.21. Its sector of activity displays an average average P / E of 24.37; therefore, it can be concluded that ILMN trades at a comparatively premium.
It should also be noted that ILMN currently has a PEG ratio of 2.77. This popular measure is similar to the well-known P / E ratio, with the difference that the PEG ratio also takes into account the expected earnings growth rate of the company. The Medical – Biomedical and Genetics sector currently has an average PEG ratio of 1.69 at the close of yesterday.
The medical – biomedical and genetic sector is part of the medical sector. The Zacks sector of this industry is currently ranked at 90, placing it in the top 36% of 250+ industries.
The Zacks industry ranking is ranked from best to worst in terms of Zacks' average ranking of individual companies in each of these sectors. Our research shows that the 50% of the top rated industries outperform the bottom half by a factor of 2 to 1.
To follow ILMN in upcoming trading sessions, be sure to use Zacks.com.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 best actions for the next 30 days. Click to get this free report
& nbsp;
Illumina, Inc. (ILMN): Free Stock Analysis Report
& nbsp;
To read this article on Zacks.com, click here."data-reactid =" 30 ">
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 best actions for the next 30 days. Click to get this free report
Illumina, Inc. (ILMN): Free Stock Analysis Report
To read this article on Zacks.com, click here.
[ad_2]
Source link